GCG and metabolic dysfunction-associated steatotic liver disease: Another meta-analysis on incretin-based medicines (GLP1-RAs and DPP-4 inhibitors) indicates the efficacy of the agents in the treatment of NAFLD patients with concurrent T2DM.